Because accepted in 2014, tucidinostat was regarded as a second-line and subsequent therapy for PTCL patients in China. Medical trials and preclinical reports in a number of hematological malignancies and strong tumors is in progress. The goal of the present period IIb study was To guage the efficacy and security https://betteq988doy0.blogsvirals.com/profile